CVE:NDVA

Indiva (NDVA) Stock Price, News & Analysis

C$0.08
+0.01 (+7.14%)
(As of 04/25/2024 05:18 PM ET)
Today's Range
C$0.07
C$0.08
50-Day Range
C$0.06
C$0.10
52-Week Range
C$0.02
C$0.13
Volume
65,214 shs
Average Volume
98,449 shs
Market Capitalization
C$14.65 million
P/E Ratio
N/A
Dividend Yield
4.04%
Price Target
C$0.15

Indiva MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
100.0% Upside
C$0.15 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
C$26,541 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.64 out of 5 stars

NDVA stock logo

About Indiva Stock (CVE:NDVA)

Indiva Limited engages in the production, processing, and sale of cannabis and cannabis related products in Canada. It offers pre-rolls, flower, capsules, and edible and extract products under the INDIVA, Indiva Life, and Artisan Batch brands. The company produces and distributes the Bhang Chocolate, Wana Sour Gummies, Jewels Chewable Tarts, Grön edibles, and Dime Industries vape products through license agreements and partnerships. Indiva Limited is based in Ottawa, Canada.

NDVA Stock Price History

NDVA Stock News Headlines

“Retirement Secret” Showed 995% Gain Last Time We Shared It
Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.
Indiva to raise up to $4M through private placement
“Retirement Secret” Showed 995% Gain Last Time We Shared It
Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.
Closing Bell: Indiva Ltd down on Wednesday (NDVA)
Indiva Ltd NDVA
Closing Bell: Indiva Ltd up on Monday (NDVA)
Indiva (OTC: NDVA.F)
Indiva Reports Second Quarter 2023 Results
Closing Bell: Indiva Ltd up on Tuesday (NDVA)
Indiva Launches No Future Gummies and Vapes
Indiva Reports First Quarter 2023 Results
Closing Bell: Indiva Ltd down on Friday (NDVA)
Indiva Reports Record Fiscal Year 2022 Results
See More Headlines
Receive NDVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Indiva and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/26/2024
Next Earnings (Estimated)
5/14/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
147,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
C$0.15
High Stock Price Target
C$0.15
Low Stock Price Target
C$0.15
Potential Upside/Downside
+100.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
C$-6,940,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$36.01 million
Cash Flow
C$0.01 per share

Miscellaneous

Free Float
N/A
Market Cap
C$14.65 million
Optionable
Not Optionable
Beta
1.11
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Carmine Marotta
    Co-Founder, President, CEO & Director
  • Ms. Jennifer Welsh
    Chief Financial Officer
  • Mr. Robert William Carse
    Chief Operating Officer
  • Mr. Sung Koo Kang
    Chief Commercial Officer
  • Mr. Pete Young
    Co-founder
  • Mark Haynes
    Vice President of Sales
  • Mr. Mitchell Stern
    Vice President of Marketing

NDVA Stock Analysis - Frequently Asked Questions

Should I buy or sell Indiva stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Indiva in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" NDVA shares.
View NDVA analyst ratings
or view top-rated stocks.

What is Indiva's stock price target for 2024?

1 Wall Street analysts have issued twelve-month target prices for Indiva's stock. Their NDVA share price targets range from C$0.15 to C$0.15. On average, they predict the company's stock price to reach C$0.15 in the next year. This suggests a possible upside of 100.0% from the stock's current price.
View analysts price targets for NDVA
or view top-rated stocks among Wall Street analysts.

How have NDVA shares performed in 2024?

Indiva's stock was trading at C$0.10 at the start of the year. Since then, NDVA shares have decreased by 21.1% and is now trading at C$0.08.
View the best growth stocks for 2024 here
.

When is Indiva's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our NDVA earnings forecast
.

What other stocks do shareholders of Indiva own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Indiva investors own include Curaleaf (CURLF), Dynavax Technologies (DVAX), Heat Biologics (HTBX), Organigram (OGI), Vaxart (VXRT), Aurora Cannabis (ACB), Acasti Pharma (ACST), Allena Pharmaceuticals (ALNA) and Energy Transfer (ET).

How do I buy shares of Indiva?

Shares of NDVA stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (CVE:NDVA) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners